Latest news with #DaVita
Business Insider
20 hours ago
- Business
- Business Insider
DaVita ‘applauds' CMMI decision to extend Kidney Care Choices Model
DaVita (DVA) issued the following statement in response to updates this week from the Center for Medicare and Medicaid Innovation related to its Kidney Care Choices Model. Misha Palecek, Chief Transformation Officer for DaVita, said: 'As a dedicated participant in the government's value-based care initiative and a pioneer in this field for the last twenty years, we applaud CMMI's decision to extend the Kidney Care Choices Model for an additional year. We believe the investments made by CMMI and participants alike will result in long-term savings in the upcoming years. The program's emphasis on comprehensive, collaborative care and patient engagement is driving encouraging health outcomes. DaVita is committed to establishing a new standard for kidney care through integrated care systems alongside our nephrology partners.' Confident Investing Starts Here:
Yahoo
a day ago
- Business
- Yahoo
DaVita Statement on Government's Kidney Care Choices (KCC) Model Updates
DENVER, May 30, 2025 /PRNewswire/ -- DaVita, a comprehensive kidney care company, issued the following statement in response to updates this week from the Center for Medicare and Medicaid Innovation (CMMI) related to its Kidney Care Choices (KCC) Model. It can be attributed to Misha Palecek, chief transformation officer for DaVita. "As a dedicated participant in the government's value-based care initiative and a pioneer in this field for the last twenty years, we applaud CMMI's decision to extend the Kidney Care Choices (KCC) Model for an additional year. We believe the investments made by CMMI and participants alike will result in long-term savings in the upcoming years. The program's emphasis on comprehensive, collaborative care and patient engagement is driving encouraging health outcomes. DaVita is committed to establishing a new standard for kidney care through integrated care systems alongside our nephrology partners." Together with participating nephrologists, DaVita launched 11 value-based care arrangements in 2022 and has since doubled that footprint to 22 Kidney Contracting Entities (KCEs). A recent report demonstrates that these value-based care arrangements result in increased transplantation, more patients dialyzing with an optimal access in place, and more patients dialyzing at home. To learn more about DaVita Integrated Kidney Care programs, visit About DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for 25 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of March 31, 2025, DaVita served approximately 282,000 patients at 3,173 outpatient dialysis centers, of which 2,661 centers were located in the United States and 512 centers were located in 13 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, helped improve health access and worked collaboratively to propel the kidney care community to adopt a higher quality standard of care for all patients, everywhere. To learn more, visit Media Contact Newsroom@ View original content: SOURCE DaVita Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
3 days ago
- Business
- Globe and Mail
$787 Billion Digital Healthcare Market Redfined: New Initiatives to Reduce Maternal Deaths and Hospital Nursing Costs from AI Powered Telehealth Company: VSee Health (Nasdaq: VSEE)
$VSEE Major Clients Include NASA, U.S. Department of Health and Human Services, McKesson, DaVita and the Entire Nation of Qatar AI-Powered Telehealth Provider with Modular, No-Code/Low-Code Platform. 1,000+ Clients Including NASA, U.S. Department of Health and Human Services, McKesson, DaVita, and the Entire Nation of Qatar. Enabling Seamless, Scalable and Secure Digital Health Solutions Across Hospitals, Governments and Enterprise Organizations. "Lego-like" Digital Health Building Blocks to Design a Flexible Telehealth System System Feature Seamless Electronic Health Record (EHR) Integration, Advanced Data Visualizations and Other Scalable Capabilities for Future Needs. Launched New AI-Powered Telehealth to Reduce Maternal Deaths in Remote Philippines. Telenursing Robotics Solution Targeting 3-5% Reduction in Hospital Nursing Costs. Strategic Hospital Pilots and Research Partnerships Position Company for Scalable Growth in $787B Digital Health Market. Shareholder Letter Issued on Company Accomplishments, Initiatives and Strong AI Powered Product Pipeline Setting a Path to Record Success in 2025 $444K County Government Contract, Expanding into Public Sector Healthcare. Partnership Agreement with LanguageLine to Boost Telehealth Adoption with Seamless, Scalable Multilingual Care. $560K Contract with Major Oncology Network. Top Kidney Care Provider to Add VSee Workflow to Oracle Cerner EHR. $2M Contract for Neurocritical Care Expansion at Leading Hospital with Autonomous Robotics and Industry-Disrupting Telenursing Model. Multiple Other Awards in 2025 including Multi-Year, $6M First Year, Government Contract to Deliver Rapid Configurable Telehealth. VSee Health (Nasdaq: VSEE) is a rapidly growing leader in AI-powered telehealth, redefining the $787 billion digital healthcare market with its modular, no-code/low-code platform. Trusted by 1,000+ clients, including NASA, the U.S. Department of Health and Human Services, McKesson, DaVita, and the entire nation of Qatar, VSEE accelerates telehealth adoption by enabling seamless, scalable and secure digital health solutions across hospitals, governments, and enterprise organizations. Field-tested with 1.5 million+ HIPAA-compliant video encounters per month, VSEE delivers turnkey solutions in critical care, teleradiology, and autonomous robotics, optimizing healthcare operations while increasing billable patient visits and provider efficiency. With a clear path to significant revenue growth and expanding margins, VSEE is positioned to become the foundational infrastructure of digital healthcare, transforming patient care, hospital workflows, and workforce utilization. VSEE has a strategic partnership with AbundaBox to launch AbundaLife™, a groundbreakinghealth record management innovative solution addresses one of the most pressing challenges in healthcare—fragmented medical records—by consolidating personal health data into one secure, comprehensive profile. AbundaLife, supported by VSEE Health's dynamic technology, empowers individuals to manage their health more effectively, enabling providers to deliver better-coordinated care and improving health outcomes. VSEE also has an agreement wih Ava Robotics, a developer of intelligent robots for the workplace, to develop telepresence solutions for the inpatient intensive care market, including the development of a VSEE -powered Ava robot that allows providers to extend their reach and provide personalized care remotely. Launch of AI-Powered Telehealth to Reduce Maternal Deaths in Remote Philippines On May 16th VSEE announced the launch of Project MAMA (Mom's AI for Maternity Aid), an innovative telehealth initiative to reduce high maternal mortality rates in rural, isolated Philippines communities of Zamboanga Sibugay. Working with maternal care physicians and specialists from Stanford University and Ateneo de Zamboanga University, VSEE technology bridges the gap in prenatal care access, enabling women in underserved areas to receive remote OB-GYN consultations via its comprehensive telehealth platform. The solution features AI chatbots responding in local languages, portable diagnostic devices (e.g. ultrasounds) and electronic health records (EHRs) — all operational within four days of deployment. The pilot program represents a VSEE broader vision of bringing accessible healthcare to underserved populations worldwide through adaptable, AI-enhanced telehealth solutions. Advanced Telenursing Robotics Solution Targeting 3-5% Reduction in Hospital Nursing Costs On April 16th VSEE announced completing development of its Telenursing Robotics solution—an AI-driven platform designed to automate routine nursing tasks and reduce labor costs. With nursing expenses representing approximately 60% of hospital operating budgets, this innovation directly targets one of the most pressing cost challenges in healthcare. Initial modeling suggests hospitals deploying the VSEE solution could reduce nursing-related expenses by 3–5%, while also enhancing patient throughput and experience. VSee Health Highlights AI-Powered Telehealth On April 2nd VSEE released an update highlighting how the Company is at the forefront, pioneering AI-driven telehealth solutions that are revolutionizing patient care. An AI-Powered, Modular Approach to Telehealth VSEE offers a modular, no-code/low-code telehealth platform that allows healthcare organizations to build customized solutions tailored to their specific needs. Dubbed as "Lego-like" digital health building blocks, this flexible system enables seamless Electronic Health Record (EHR) integration, advanced data visualizations, and scalable capabilities that prepare healthcare institutions for the future. Expanding Partnerships and Strategic Growth The VSEE growing client portfolio and strategic partnerships further cement its leadership in the digital health space: Government Expansion: A $444K county government contract to provide a white-label telehealth and data analytics platform for mental and behavioral health services, signaling VSEE expansion into public sector healthcare. Major Oncology Network: A $560K contract to implement a secure telehealth platform, showcasing VSEE ability to scale within specialty healthcare. Oracle Cerner EHR Integration: A partnership with a top kidney care provider to integrate VSEE workflow into Oracle Cerner EHR, boosting telehealth call completion rates by 88%. Robotic Innovations: A $2 million contract with a leading hospital for neurocritical care expansion, leveraging autonomous robotics and an industry-disrupting telenursing model. Government Multi-Year Contract: A multi-year contract valued at $6 million in its first year, allowing VSEE to deliver rapid-configurable telehealth solutions for a national healthcare program. Strategic Collaborations for Enhanced Telehealth Adoption Beyond direct contracts, VSEE is accelerating telehealth adoption through groundbreaking partnerships: AbundaBox Collaboration: Launching AbundaLife, a health record management platform that consolidates fragmented medical records into a secure, comprehensive profile. Ava Robotics Partnership: Developing telepresence robots for inpatient intensive care, enabling remote providers to offer real-time, personalized care. LanguageLine Solutions Integration: Facilitating one-touch interpreter access in over 240 languages, ensuring seamless multilingual healthcare services. Field-Tested, Scalable, and Secure Digital Health Infrastructure With over 1.5 million HIPAA-compliant video encounters per month, VSEE delivers turnkey telehealth solutions in critical care, teleradiology, and autonomous robotics. VSEE technology enhances hospital operations by increasing billable patient visits and optimizing provider efficiency. This ability to streamline operations while ensuring high-quality patient care positions VSEE as a foundational infrastructure provider in digital healthcare. Outlook Following Nasdaq Listing Since listing on Nasdaq in mid-2024, VSEE has expanded its market presence while navigating short-seller activity, a common occurrence among companies following SPAC mergers. The company reports a growing portfolio of contracts and continues to develop its AI-driven product offerings, with further updates expected in 2025. For more information on $VSEE visit: Disclosure listed on the CorporateAds website Media Contact Company Name: Vsee Health, Inc. Contact Person: Anne Chang Email: Send Email Phone: 626-513-1824 Address: One Gateway Center Suite 507 300 Washington St. City: Newton State: Massachusetts Country: United States Website:
Yahoo
20-05-2025
- Business
- Yahoo
DaVita Inc. Announces Upsize and Pricing of $1 Billion Senior Notes Offering
DENVER, May 20, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) ("DaVita") announced today the upsize and pricing of its previously announced private offering (the "offering") of its 6.750% senior notes due 2033 (the "2033 notes"). The aggregate principal amount of the 2033 notes offered in the offering was increased from $750 million to $1 billion, and the 2033 notes were priced at 100.000% of their face amount to yield a 6.750% coupon. The offering is expected to close on May 23, 2025, subject to satisfaction of customary closing conditions. DaVita intends to use the net proceeds from the offering (i) to repay outstanding revolving credit facility borrowings, together with related accrued and unpaid interest thereon, (ii) to pay any costs, fees and expenses in connection with the foregoing, and (iii) if any proceeds remain, for general corporate purposes, including, without limitation, for repurchases of capital stock, working capital and capital expenditures. The 2033 notes were offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and to certain non-U.S. persons in transactions outside the United States in compliance with Regulation S under the Securities Act. The offer and sale of the 2033 notes have not been and will not be registered under the Securities Act or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This release does not constitute an offer to sell or the solicitation of an offer to buy the 2033 notes, nor will there be any sale of the 2033 notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. About DaVita DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for 25 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. Forward-Looking Statements This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA") and the federal securities laws. All statements in this release, other than statements of historical fact, are forward-looking statements and as such are intended to be covered by the safe harbor for "forward-looking statements" provided by the PSLRA. Without limiting the foregoing, statements including the words "expect," "intend," "will," "could," "plan," "anticipate," "believe" and similar expressions are intended to identify forward-looking statements. These forward looking statements include, but are not limited to, expectations regarding the offering, the use of the net proceeds therefrom, and the anticipated date of closing thereof. Actual future events and results could differ materially from any forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things: external conditions, including those related to general economic, marketplace and global health conditions, including without limitation, the impact of global events and political or governmental volatility; the impact of the domestic political environment and related developments on the current healthcare marketplace, our patients and on our business; the continuing impact of the COVID-19 pandemic on our financial condition and the chronic kidney disease ("CKD") population and our patient population; supply chain challenges and disruptions, including without limitation with respect to certain key services, critical clinical supplies and equipment we obtain from third parties, and including any impacts on our supply chain and cost of supplies as a result of natural disasters or evolving trade policies, including tariffs; the potential impact of new or potential entrants in the dialysis and pre-dialysis marketplace and potential impact of innovative technologies, drugs, or other treatments on our patients and industry; elevated teammate turnover or labor costs; the impact of continued increased competition from dialysis providers and others; and our ability to respond to challenging U.S. and global economic and marketplace conditions, including, among other things, our ability to successfully identify cost saving opportunities; the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates; a reduction in the number or percentage of our patients under commercial plans, including, without limitation, as a result of continuing legislative efforts to restrict or prohibit the use and/or availability of charitable premium assistance, or as a result of payors implementing restrictive plan designs; risks arising from potential changes in or new laws, regulations or requirements applicable to us, including, without limitation, those related to trade policy, healthcare, privacy, antitrust matters, and acquisition, merger, joint venture or similar transactions and/or labor matters, and potential impacts of changes in interpretation or enforcement thereof or related litigation impacting, among other things, coverage or reimbursement rates for our services or the number of patients enrolled in or that select higher-paying commercial plans, and the risk that we make incorrect assumptions about how our patients will respond to any such developments; our ability to successfully implement our strategies with respect to integrated kidney care and value-based care initiatives and home based dialysis in the desired time frame and in a complex, dynamic and highly regulated environment; a reduction in government payment rates under the Medicare End Stage Renal Disease program, state Medicaid or other government-based programs and the impact of the Medicare Advantage benchmark structure; our reliance on significant suppliers, service providers and other third party vendors to provide key support to our business operations and enable our provision of services to patients, including, among others, suppliers of certain pharmaceuticals, administrative or other services or critical clinical products; and risks resulting from a closure, reduction or other disruption in the services or products provided to us by such suppliers, service providers and third party vendors; noncompliance by us or our business associates with any privacy or security laws or any security breach by us or a third party, such as the recent cybersecurity incident experienced by DaVita, including, among other things, any such non-compliance or breach involving the misappropriation, loss or other unauthorized use or disclosure of confidential information; legal and compliance risks, such as compliance with complex, and at times, evolving government regulations and requirements, and with additional laws that may apply to our operations as we expand geographically or enter into new lines of business; our ability to attract, retain and motivate teammates, including key leadership personnel, and our ability to manage potential disruptions to our business and operations, including potential work stoppages, operating cost increases or productivity decreases whether due to union organizing activities, legislative or other changes, demand for labor, volatility and uncertainty in the labor market, the current challenging and highly competitive labor market conditions, including due to the ongoing nationwide shortage of skilled clinical personnel, or other reasons; changes in pharmaceutical practice patterns, reimbursement and payment policies and processes, or pharmaceutical pricing, including with respect to oral phosphate binders, among other things; our ability to develop and maintain relationships with physicians and hospitals, changing affiliation models for physicians, and the emergence of new models of care or other initiatives that, among other things, may erode our patient base and impact reimbursement rates; our ability to complete and successfully integrate and operate acquisitions, mergers, dispositions, joint ventures or other strategic transactions on terms favorable to us or at all; and our ability to continue to successfully expand our operations and services in markets outside the United States, or to businesses or products outside of dialysis services; the variability of our cash flows, including, without limitation, any extended billing or collections cycles including, without limitation, due to defects or operational issues in our billing systems, the impact of the recent cybersecurity incident experienced by DaVita or defects or operational issues in the billing systems or services of third parties on which we rely; the risk that we may not be able to generate or access sufficient cash in the future to service our indebtedness or to fund our other liquidity needs; the effects on us or others of natural or other disasters, public health crises or severe adverse weather events such as hurricanes, earthquakes, fires or flooding; factors that may impact our ability to repurchase stock under our share repurchase program and the timing of any such stock repurchases, as well as any use by us of a considerable amount of available funds to repurchase stock; our goals and disclosures related to environmental, social and governance ("ESG") matters, including, among other things, evolving regulatory requirements affecting ESG standards, measurements and reporting requirements; and the other risk factors, trends and uncertainties set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the period ended March 31, 2025 and the other risks and uncertainties discussed in any subsequent reports that we file or furnish with the U.S. Securities and Exchange Commission from time to time. The forward-looking statements should be considered in light of these risks and uncertainties. All forward-looking statements in this release are based solely on information available to us on the date of this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise, except as may be required by law. Contact Information Investors:IR@ View original content to download multimedia: SOURCE DaVita Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18-05-2025
- Business
- Yahoo
Warren Buffett Sells $168M in DaVita Inc. (DVA) Shares
According to a Form 4 filing with the United States Securities and Exchange Commission, on May 8, Berkshire Hathaway sold 1,145,938 shares of DaVita Inc. (NYSE:DVA), valued at $168.58 million. The move occurred just a day before a union health benefits fund sued top dialysis services providers in the country, including DaVita Inc. (NYSE:DVA), for allegedly artificially inflating treatment costs for billions of dollars. Clinical laboratory technicians running tests in the comprehensive kidney care services. The class action lawsuit accused DaVita and Fresenius Medical Care of illegally carving up areas in the US to avoid competition. The plaintiffs added that the two companies colluded in parallel price increases that were higher than those of competitors and not explained by market forces. DaVita has denied the allegation as baseless and vowed to defend itself vigorously against it. The sell-off just a day before the lawsuit has once again proven Warren Buffett's business foresight, which has been a cornerstone of Berkshire's success. Despite the recent trade, DaVita Inc. (NYSE:DVA) remains a top pick from the 94-year-old's stock portfolio, with holdings of over $5 billion in the company. DaVita Inc. (NYSE:DVA) is one of the largest kidney dialysis providers in the US with 2,657 centers. The company also operates 509 dialysis centers in 13 other countries. The stock has surged by 4% in the past 12 months. While we acknowledge the potential of DVA, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DVA and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Cheap Rising Stocks to Buy Right Now and ChatGPT Stock Advice: Top 12 Stock Recommendations. Disclosure: None.
